Subscribe
type here...
Subscribe

Tag: Bristol Myers Squibb

Bristol Myers must face $6.4 bln lawsuit over delayed cancer drug

Global Markets Pharma -
A U.S. judge on Friday refused to dismiss a $6.4 billion lawsuit accusing Bristol Myers Squibb Co of delaying...

Bristol Myers Squibb announces a $4.1 billion deal to acquire Turning Point Therapeutics

Global Markets Pharma -
Pharmaceutical giant Bristol Myers Squibb Company announced a $4.1 billion deal for Turning Point Therapeutics Inc  on Friday morning,...

BMS, Merck enter into $2.3 billion partnership with Amphista to discover and develop small molecule protein degraders

Drug Development Pharma -
Amphista Therapeutics, a global leader in the discovery and development of next generation targeted protein degradation (TPD) therapeutics, May...

Bristol Myers Squibb sales grew in Q1 due to growth in line products

Global Markets Pharma -
Pharmaceutical company, drug maker Bristol Myers Squibb on Friday posted slightly higher-than-expected first-quarter earnings thanks to increased sales of...

Nektar Therapeutics and Bristol Myers Squibb stop clinical trials for key cancer drug

Global Markets Pharma -
Nektar Therapeutics and Bristol Myers Squibb announced that based on results from pre-planned analyses of two late-stage clinical studies...

FDA approves Bristol Myers’ Opdualag cancer immunotherapy

Approvals Pharma -
Bristol Myers Squibb announced that OpdualagTM, a new, first-in-class, fixed-dose combination of nivolumab and relatlimab, administered as a single...

U.S FDA approves expanded use of Bristol Myers lung cancer medication

Regulatory Pharma -
Bristol Myers Squibb announced that the U.S. Food and Drug Administration (FDA) approved Opdivo®(nivolumab) in combination with platinum-doublet chemotherapy...

Eisai and BMS Enter Into Strategic Collaboration for MORAb-202 Antibody Drug Conjugate

Drug Development Pharma -
Bristol Myers Squibb will pay $650 million U.S. dollars to Eisai including $200 million U.S. dollars as payment toward Eisai research and development expenses.

PHARMPROM is a premier digital resource for the pharmaceutical sector, combining breaking news, deep insights, and key market events. We cover the entire product lifecycle—from R&D and manufacturing to distribution—in strict accordance with Good Pharmaceutical Practices (GxP).

Disclaimer All content on pharmprom.net is for informational purposes only and does not constitute medical advice. The materials are intended exclusively for industry professionals and are not addressed to the general public.

Company

Headlines

Newsletter

Get important news delivered directly to your inbox and stay connected!

© PHARMPROM 2026